companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2024
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -55,000 and a net result of DKK 7,000 compared with DKK 5,000 the year before. Equity amounted to DKK 1,795,000. The solvency ratio was 97.3%.
- Gross Profit
- -55,000 kr.
- Profit/Loss
- 7,000 kr.
- Equity
- 1,795,000 kr.
- Total Assets
- 1,845,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -55 t. | 7 t. | 1.8 mio. | - |
| 2023 | - | -53 t. | 5 t. | 1.8 mio. | - |
| 2022 | - | -6 t. | 4 t. | 1.8 mio. | - |
| 2021 | - | - | -37 t. | 1.8 mio. | - |
| 2020 | - | - | -108 t. | 1.8 mio. | - |
How creditworthy is Novo Nordisk Invest 4 A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Novo Nordisk Invest 4 A/S has published its annual report for 2023. Gross profit came to DKK -53,000, and the net result was DKK 5,000.
As of May 23, 2024, John Francis Kuckelman has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of May 23, 2024, Kristine Aachmann Bethe has left the board of directors of Novo Nordisk Invest 4 A/S.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.